Navigation Links
NYU scientists identify critical protein complex in formation of cell cilia
Date:8/19/2008

NEW YORK, August 19, 2008 An international team led by NYU Cancer Institute have identified a protein complex that regulates the formation of cilia, which are found on virtually all mature human cells and are essential to normal cell function.

The new report, published this week by Developmental Cell and selected as the featured publication of the open-access online edition, describes how three proteins work together to regulate the formation of primary cilia. The study led by Brian Dynlacht, Ph.D., professor of pathology and director of NYU Cancer Institute Genomics Facility, investigates these antenna-like structures, once thought to be vestigial remnants of cell evolution, which have recently emerged as a focal point of research in developmental cell biology.

"We are trying to understand the regulation of processes that are fundamental to normal cell development and health in humans," said William Y. Tsang, Ph.D., of the NYU School of Medicine and Cancer Institute, and first author of the paper. "Defective cilia are implicated in a wide range of serious illnesses such as polycystic kidney disease, retinal degeneration, and neurological disorders. Inappropriate activation of signaling molecules that normally reside at the primary cilium, may lead to certain cancers."

At the center of the process lies the protein CEP290, which normally promotes primary cilia formation in mature cells. Dr. Tsang and his colleagues discovered that a second protein, CP110, normally suppresses the function of CEP290 until cells are fully mature. At that point, CP110 is destroyed, freeing CEP290 to interact with a third protein, Rab8a, to promote cilia formation on the surface of the mature cell.

The team's findings may help to identify potential targets for future drug design.

"Ciliogenesis is a fundamental process. These structures are found in almost every type of human cell you can imagine," Dr. Tsang said. "If we can e
'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Johns Hopkins scientists discover what drives the development of a fatal form of malaria
2. Smithsonian scientists discover new bird species
3. Scientists discover major genetic cause of colorectal cancer
4. Scientists overcome nanotech hurdle
5. Strange molecule in the sky cleans acid rain, scientists discover
6. Scientists team up in Houston to tackle global challenges
7. Scientists find elephant memories may hold key to survival
8. Scientists to assess Beijing Olympics air pollution control efforts
9. Scripps scientists will assess Beijing Olympics air pollution control efforts
10. Midge-hunting scientists tackle spread of devastating bluetongue virus
11. Scientists a step closer to producing fuel from bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ital to your health as what you eat, found researc... Their experiments in mice revealed that the daily...verthe body,s metabolic clearinghouseis mostly con...dian clock as conventional wisdom had it. , "If...umber of genes completely independent of the circa...
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 1Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 2Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 3Go to the doctor 3F Only if Im really sick 52314 1Go to the doctor 3F Only if Im really sick 52314 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3
...INGTON, Va., June 10 Stanley, Inc. (NYSE:,SXE), a...ssional services,to the U.S. federal government, a...ve agreement to acquire Oberon Associates, Inc. (O...d information technology services,company. The pur...cash,subject to certain working capital and other ...
...Scientists at the Institute of Food Research have ...re vulnerable to the development of tumours. , W... Biotechnology and Biological Sciences Research Co...ntrol these changes and delay or reverse the onset...hat play a role in the very earliest stages of col...
...Monash University research into heavy metal contam... the Gippsland Lakes has revealed high mercury lev.... , Researchers from the School of Biological Sc...he dolphins were within a range considered to caus...er than mercury levels found in populations around...
Other Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4'Addicted' cells provide early cancer diagnosis 2Mercury contamination found in stranded Victorian dolphins 2
(Date:11/24/2009)...EYKJAVIK, Iceland, November 24 /PRNewswire-FirstCa... announced the approval of all of its,"first day" ...ict of Delaware,(the "Bankruptcy Court"). deCODE l...er Chapter 11 of the United States Bankruptcy Code...issued by the Bankruptcy Court allow the company t...
(Date:11/24/2009)... Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy ann...ation (SFDA) has approved the,investigational new ...t,(Nodlin), an innovative insulin formulation to t... initiate its first phase I clinical study. ,... blood glucose and poor,metabolism. The complicati...
(Date:11/24/2009)...cacy endpoint has been met for patients with advan..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - ...the "Company"), a global biopharmaceutical company...announced positive efficacy data from a Phase 2 st... AEZS-108 (formerly AN-152), in patients with adva...
(Date:11/24/2009).... 24, 2009 Arena Pharmac...that the company is scheduled to present at the Pi...December 1, 2009 at 11:30 a.m. Eastern Time (8:30 ... New York City. Jack Lief, Arena,s President and C... overview of the company, including its clinical d...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... 12 Anthera Pharmaceuticals, Inc., a,privately he...mmatory drugs,announced today that it has complete...urrent Acute coronary events with Near-term Cardio...designed to examine the impact of,varespladib (A-0...of an Acute,Coronary Syndrome (ACS) event. , "...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced toda...have agreed with the FDA on the final design for a... of hepatitis C (HCV), slated to initiate in the f...at R7128 is advancing into a large phase 2b trial,...ief Medical Officer. "R7128 is the most advanced n...
...nuary 12 , - Reflects Strong International Gr...ding IP Management Specialist and Legal Support Se...llectual property,( http://www.cpaglobal.com ) (IP...outsourced legal support services, has today marke...ew brand worldwide. , Founded in 1969 as a spe...
Other Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
Rat IgG2b Clone: A95-1, Allophycocyanin Conjugated/Tagged from BD Biosciences Pharmingen
Rabbit Anti-Human Sphingosine 1-phosphate receptor Edg-1 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Rat Albumin EIA Kit from Cayman Chemical
CMV IgM ELISA Kit, Single from Bio-Quant Inc.
Biology Products: